Allogeneic hematopoietic SCT is indicated for children whose disease demonstrates dismal prognosis with chemotherapy. This study aims to analyse the most recent outcomes of unmanipulated haploidentical (HID) HSCT for paediatric patients with acute leukaemia. Those from matched sibling donors (MSD) HSCT provided a parallel cohort to illustrate the benefits of HID. Conditioning regimen was modified BuCy2. Anti-thymoglobulin was used for HID. Mobilised marrow and blood stem cells were used as the grafts. All patients in HID achieved neutrophil recovery and 96.7% platelet recovery. In HID, the incidences of acute GVHD 3-4 and extensive chronic GVHD were 14.3 and 26.6%. Play-performance score 90-100% was recorded in 79.7% of all survivors. The 5-year leukaemia-free survival (LFS) in CR1, CR2, beyond CR2 or non-remission were 68.9%, 56.6%, 22.2% and 82.5%, 59.4%, 42.9% for ALL and AML, respectively. In MSD group, LFS for ALL and AML in CR1 were 62.5 and 71.7%. Outcomes of the HID HSCT for paediatric patients with acute leukaemia showed benefits that were similar to those of the parallel cohort of MSD HSCT.
INTRODUCTION
Great progress has been achieved in chemotherapy for paediatric patients with acute leukaemia. The probabilities of 5-year leukaemia-free survival (LFS) have been reported to be as high as 80-90% for ALL 1 and 40-60% for AML. 2 However, allogeneic haematopoietic SCT is indicated for patients whose disease demonstrates dismal prognosis with chemotherapy. Data from Chinese paediatric studies showed lower LFS compared with data from Europe and America in standard-and intermediate-risk ALL, as well as in intermediate-and high-risk AML. 3, 4 Hence, the domestic indications for allogeneic HSCT in paediatric patients with acute leukaemia cover more subtypes of disease. 5 For paediatric patients requiring allogeneic HSCT, it is widely accepted that grafts from matched sibling donors (MSDs) result in the best outcomes among various sources of stem cells. For patients lacking a suitable HLA-compatible related donor, alternative options include unrelated donors or umbilical cord blood followed by a haploidentical donor (HID) among family members. At present, there is no international or regional consensus or recommendation to guide alternative options for alternative donors. Haematopoietic cells from relatives who are HLA HID are an immediate almost available source of grafts for HSCT candidates. For HSCT with related HIDs, extensive T-cell depletion or CD34 þ cell selection in vitro, mega-dose infusion and other supportive techniques have increased the rate of engraftment, reduced TRM and improved survival. 6, 7 The latest reports of T-cell depletion HSCT from HID parental donors showed improved outcomes in the recent treatment era, with 5-year OS rates of 65% and 74% for very high-risk ALL and AML patients, respectively. 8 At our institution, promising results with unmanipulated, HID HSCT have been achieved in adult patients without ex vivo T-cell depletion, demonstrating outcomes similar to those with MSDs and well-matched unrelated HSCT. 9, 10 The short-term efficacy and safety of this HID transplantation setting was also reported in 42 paediatric patients, including 36 patients with acute leukaemia.
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The long-term outcomes of unmanipulated HID HSCT, based on large numbers of paediatric patients, have not been clear. We analysed herein the most recent outcomes with related HID HSCT for paediatric patients with acute leukaemia. The results of allogeneic HSCT from MSDs provided a parallel cohort to illustrate the similar benefits of HSCT from HIDs.
MATERIALS AND METHODS

Patients with HID donors
Two-hundred twelve patients (between 3-and 18-years-old) with acute leukaemia, who were indicated for allogeneic hematopoietic SCT, were enrolled between May 2002 and December 2011 ( Table 1 ). The outcomes of 36 patients among them were reported in 2008, and these patients were followed up in this study. All of the patients lacked (1) MSDs; (2)X8/10 HLA matched unrelated donors; and (3) umbilical cord blood units with nucleated cellsX4 Â 10 7 /kg recipient body weight and X4/6 HLA matched antigen with molecular typing. During the same period, 28 patients received allogeneic hematopoietic SCT from unrelated donors, and 34 patients received HSCT from umbilical cord blood. The order of preference of donor selection was identical sibling, an unrelated donor and umbilical cord blood, followed by a related HID donor. Patients with any uncontrolled infections or with severe hepatic, renal, pulmonary or cardiac diseases were not eligible for HSCT. This study was approved by the Institutional Review Board of Peking University, and written informed consent was obtained from the parental guardians of all of the patients and their donors.
Transplantation procedures for HID HSCT
All of the patients were treated with the homogeneous modified BuCy2 and anti-thymoglobulin regimen, consisting of the following: Ara-C (4 g/m 2 per day, i.v.) on days À 10 and À 9; BU (4 mg/kg per day, orally or 3.2 mg/kg per day, i.v. in four doses daily) on days À 8, À 7 and À 6; CY (1.8 g/m 2 per day, i.v.) on days À 5 and À 4; and semustine (250 mg/m 2 , orally) on day À 3. Anti-thymoglobulin (rabbit, Sangstat product, 2.5 mg/kg per day, i.v.) was administered on days À 5 to À 2. All of the transplant recipients received CsA, mycophenolate mofetil and short-term MTX for GVHD prophylaxis. CsA (3 mg/kg, q12h, i.v.) was used from day À 9, of which the trough concentration was adjusted to 150-250 ng/mL. It was switched to oral administration when the patient's bowel function returned to normal. From day À 9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was tapered to half until day þ 60 and was discontinued thereafter. Following graft infusion, a dose of 15 mg/m 2 of MTX was administered i.v. on day þ 1, as well as a dose of 10 mg/m 2 on days þ 3, þ 6 and þ 11. Donors younger than 8-years-old and with body weight o30 kg were excluded due to concerns about the safety of stem cell donation and due to technical limitation for apheresis. Harvesting of G-CSF-primed BM and G-CSF mobilised peripheral blood has been described in detail.
12 G-CSF mobilised peripheral blood was used as the only graft source in patients whose donors would not consent to marrow donation.
Supportive care
Fluconazole was administered to all patients, from day À 9 to engraftment for patients with MSD or to day þ 70 for those with HID, for primary prophylaxis against invasive fungal infections from Candida albicans. i.v. itraconazole (or other antifungal agents that were effective in the medical history) was used for secondary prophylaxis against invasive fungal infections from day À 9 to day þ 90. Trimethoprim sulfamethoxazole was administered twice daily for prophylaxis of Pneumocystis carinii pneumonia from day À 9 to day þ 30 and then twice weekly until day þ 180. Acyclovir was administered orally from day þ 1 to year 1.5 for prophylaxis of HSV infection, and ganciclovir was routinely administered i.v. from day À 9 to À 2 for prophylaxis against CMV infection.
Patients were monitored twice weekly for CMV antigenaemia with RQ-PCR. Patients with CMV antigenaemia (positive in two consecutive tests) received pre-emptive therapy with ganciclovir or foscarnet if pancytopenia was present, which was discontinued after two consecutive negative tests. EBV was monitored twice weekly with QPCR. Rituximab was administered if EBV viraemia was persistently positive with any of the symptoms, such as fever or enlargement of the lymph nodes. Patients were monitored twice weekly by Galactomannan assay for Aspergillus and received pre-emptive therapy with i.v. itraconazole, caspofungin, voriconazole or amphotericin B if the surveillance tests or computed tomography scans were positive. Patients received prophylactic antibiotics when the number of neutrophils was o1.0 Â 10 9 /L. Computed tomography scans and lung function tests were performed in all patients before they entered the laminar flow room. Plain-film chest radiography was then performed once per week before engraftment. Computed tomography scans and arterial blood gas analysis were performed whenever patients developed fevers or respiratory symptoms (for example, cough and dyspnoea). When symptoms or signs of infection occurred in patients on prophylaxis, additional anti-infection agents were added based on clinical status and the results of microbiological studies.
Pre-emptive intervention with modified DLI was planned for patients who showed positive detection of minimal residual disease (MRD) after transplantation. 13 All of the patients received G-CSF from day þ 6 to myeloid recovery. Supportive care for blood infusion and chimerism monitoring has been described previously. 9 Definitions and end points
The indications for allogeneic HSCT are provided in Table 2 . All of the patients were monitored for MRD after transplantation using leukaemia-associated immunophenotypes and WT1. [14] [15] The median doses of mononuclear cells and CD3 þ cells for pre-emptive mDLI were 1.0 (0.9-1.6) Â 10 8 /kg and 0.42 (0.2-0.8) Â 10 7 /kg, respectively. Intermediate-resolution DNA techniques were used to determine HLA-A and -B status, and high-resolution techniques were used to determine C, DRB1 and DQB1 loci. Days before transplantation are preceded by '-', and days after the last stem cell infusion are preceded by ' þ '. For all of the surviving patients, the end point of the last follow-up was 30 October 2012. Engraftment, GVHD, OS, LFS, TRM and relapse were calculated from day þ 1. The date of neutrophil recovery was defined as the first day of 3 consecutive days that an ANC of 0.5 Â 10 9 /L was achieved. The date of platelet recovery was defined as the first day of 7 consecutive days that an absolute platelet count of 20 Â 10 9 /L was achieved, without the aid of transfusion. Acute and chronic GVHD were diagnosed and graded by the transplantation centre, according to defined criteria. 16 Relapse was defined as haematological leukaemia recurrence.
Statistical analysis
The incidences of acute and chronic GVHD, TRM, and leukaemia relapse were calculated using cumulative incidence curves to accommodate competing risks. Assessments of potential risk factors for outcomes were evaluated by multivariate analysis using Cox proportional hazards regression. Factors that were significant at the 2% level were retained in the final model. The following variables were considered in multivariate analysis: the age and sex of the patients; sex and relationship pairs between donor and recipient; interval from diagnosis to transplantation; degree of HLA disparity; graft type; CD34 þ cells infused in grafts; diagnosis of acute leukaemia (ALL vs AML) and its remission status before transplantation (CR1/CR2 vs beyond CR2 and non-remission (NR)); the occurrence of acute or chronic GVHD and treatment era (02-07 vs 08-11). The SAS statistical software package, version 8.2 (SAS institute, Cary, NC, USA) was used for all of the analyses.
Data of patients with MSDs
Forty-six patients (ALL: 27; AML: 15) who received HSCT consecutively between August 2001 and December 2011 were included in this cohort. Forty-two patients were in CR1, and four were in NR status before HSCT. All of the patients were treated with a modified BuCy2 regimen consisting of the following: hydroxyurea (80 mg/kg, orally in 2 doses) on day À 10; Ara-C (2 g/m 2 /day, i.v.) on day À 9; and BU, CY and semustine (with the dosages the same as those for HID). For GVHD prophylaxis, CsA was used as above; mofetil was discontinued on the day of myeloid recovery, and MTX was administered on days þ 1, þ 3 and þ 6.
RESULTS
Engraftment of patients with HID donors
All 212 patients achieved neutrophil recovery with full donor chimerism at a median of 13 (9-28) days. Two-hundred five (96.7%) patients achieved platelet recovery at 25 (7-180) days. No risk factors for platelet engraftment failure were identified in multivariate analysis. There was no impact of HLA disparity on neutrophil or platelet recovery.
GVHD in patients with HID donors Fifty-three (25.0%) of the total 212 patients developed acute GVHD grade 2, and 23 (10.8%) developed grade 3-4. The cumulative incidence of acute GVHD grades 2-4 and those of grades 3 and 4 are provided in Table 3 . No risk factors, including HLA disparity, were found for the occurrence of acute GVHD grade 2-4 or 3-4. In the 193 patients (91.0%) who were alive at day 100, chronic GVHD occurred in 42 (22.8%) patients; 27 of them (14.0%) had extensive disease. The cumulative incidences of chronic GVHD and the extensive type of the disease at 5 years are provided in Table 3 . Multivariate analyses showed that patients who did not develop preacute GVHD grade 3-4 had a significantly lower risk of occurrence of chronic extensive GVHD (relative risk (RR) 0.26, P ¼ 0.02), compared with those who developed acute GVHD grade 3-4.
Survival of patients with HID donors A total of 143 patients (ALL: 85; AML: 58) survived to the end point of the final follow-up, with 136 (ALL: 78; AML: 58) achieving LFS. Comparisons of the probabilities of OS and LFS between ALL and AML patients in HID group were provided in Table 4 . Multivariate analysis identified that patients who were in CR1/CR2 before HSCT had higher OS (RR ¼ 2.31, P ¼ 0.015) than those in beyond CR2 or NR before transplant. Patients with ALL had inferior LFS (RR ¼ 0.51, P ¼ 0.037) compared with those with AML. Patients who received transplants during 08-11 had higher OS and LFS than those transplanted during 02-07 (RR ¼ 2.05, P ¼ 0.019; RR ¼ 1.91, P ¼ 0.025). The results from a sub-analysis for CR1/CR2 patients in era of 08-11 and compared with those in the era of 02-07 showed a significant difference for OS but not for LFS (Table 5) .
The scores on the Play-Performance Scale after HSCT were evaluated for all 143 survivors. Five patients (3.5%) scored 50-60%, 24 (16.8%) scored 70-80%, 18 (12.6%) scored 90% and 96 (67.1%) scored 100%. Four of 7 patients who relapsed and then survived in remission scored 80-100%, and the other three patients scored 50-70%.
TRM and causes of death in patients with HID donors Thirty-two (ALL: 23, 71.9%; AML: 9, 28.1%) of the total of 212 patients died of transplantation-related toxicities. Higher TRM was found in patients who were in beyond CR2 or NR before transplant, compared with CR1/CR2 patients (RR ¼ 2.47, P ¼ 0.030). The occurrence of acute GVHD grade 3-4 was identified as a risk factor for TRM (P ¼ 0.027). No effect of HLA disparity on TRM was recorded.
For patients with ALL, infection was the most common cause of death. Ten (43.5%) patients died of infections (one in the central nervous system and nine in the lung), seven (30.5%) of GVHD (four of acute GVHD grade 3-4 and three of chronic GVHD complicated with infection), three (13.0%) of post transplantation lymphoproliferative disorder, one (4.3%) of discontinuation of treatment for pneumonia due to unwillingness, one of pulmonary infarction and one of heart failure. Among patients with AML, 2 (22.2%) died of infections (one in the central nervous system and one in the lung), All of the patients with ALL t (9;22) were indicated for allogeneic HSCT after CR1 was achieved due to limited financial sources for the use of imatinimb. Haploidentical transplantation for children D-H Liu et al 3 of GVHD (one of acute grade 4 and two of chronic GVHD complicated with infection), 2 of post transplantation lymphoproliferative disorder, one (11.1%) of poor engraftment and one of a cardiac infarction. One patient who had poor engraftment on day þ 34 received a second HSCT from the same HID donor. He died of acute GVHD grade 4 on day þ 81 after the first HSCT (day þ 40 after the second HSCT).
Relapse of patients with HID donors Forty-four patients relapsed (ALL: 32; AML: 12). Patients in beyond CR2 or NR before transplant had a significantly higher incidence of relapse (RR ¼ 3.89, P ¼ 0.000) than those in CR1/CR2. Among the ALL patients, 28 (87.5%) experienced haematological relapse; two relapsed in the central nervous system and two relapsed in the testis. Twenty-five patients died of relapse. Among eight patients who received chemotherapy or radiation therapy followed by modified DLI, seven (four with haematological relapse and three with extramedullary relapse) were alive at a median follow-up of 15 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) months after the diagnosis of relapse. Among the 12 AML patients who had haematological relapses, 2 received chemotherapy, followed by modified DLI, but they died of relapse at 4 and 6 months after their relapses, respectively.
Eighteen patients (ALL: 13; AML: 5) were diagnosed as MRDpositive at a median of 6 months after transplantation, and they received modified DLI as a pre-emptive intervention for potential relapse. Among the 13 patients with ALL, 9 (69.2%) patients achieved LFS, 2 died of relapse, and 2 died of TRM; among 5 AML patients, 2 (40.0%) achieved LFS, 1 died of relapse and 2 died of TRM.
Cohort data of patients with MSDs All 46 patients achieved myeloid recovery at a median of 16 (9-24) days after HSCT and 45 (97.8%) patients achieved platelet recovery at 16 (7-26) days. Seven patients (15.2%) developed acute GVHD: 3 with grade 1, 1 with grade 2, 2 with grade 3 and 1 with grade 4. Seven (15.9%) of the total of 44 patients who survived more than 100 days after HSCT developed chronic GVHD and 2 of them had the extensive type. Thirty-three (71.7%) patients (ALL: 20; AML: 13) survived and 31 (67.4%) achieved LFS (ALL: 19; AML: 12). In total, four patients (ALL: 3; AML: 1) died of TRM and ten (ALL: 8; AML: 2) relapsed. The incidence of acute GVHD grade 2-4, grade 3-4, chronic GVHD, extensive chronic GVHD and the 5-year probabilities for OS, LFS, TRM and relapse are provided in Table 4 for ALL and AML patients, respectively.
DISCUSSION
The current study, with 4200 cases of HID HSCT, consolidates the results of our previous report of 42 paediatric patients. Although it is difficult to compare the results from HID cohorts to those from matched sibling cohorts due to the relatively small number of subjects in the MSD group, data from MSD could provide a point of reference to demonstrate the outcomes of HSCT from HIDs. The outcomes in the present study were among the best ones yet reported for HID HSCT, demonstrating the benefits of this transplant strategy for children and young adolescents with acute leukaemia. Survivals in our report seemed to be higher than those from European studies and close to those from the United States. In the recent European Blood and Marrow Transplant group report of very high-risk ALL patients from multiple centres, the 5-year LFS Table 4 . OS, LFS, TRM and relapse after transplantation from HID or MSD in paediatric patients with acute leukemia rates were 30%, 34%, 22% and 0% for CR1, CR2 or CR3/in relapse, respectively. 17 Leung et al. 8 reported a high success rate with T-cell depleting HID HSCT in children who showed a 5-year OS of 88% in a recent cohort. However, comparisons among different reports are not reliable. Many paediatric patients in CR1/CR2 were enrolled in our current study and these patients received transplants in relatively early stage of disease, compared with the patients in the European Blood and Marrow Transplant group study. As a consequence, this difference might have contributed to the relatively higher survivals in our report. Relapses in the NR and beyond CR2 group were still high, which indicates that the GVL effect in our current protocols must be further improved.
Engraftment failure in HID HSCT with ex vivo T-cell depletion has been overcome by mega-dose CD34 þ cell infusion. The engraftment rates in recent reports ranged from 91% to 96% (92 and 27 patients, respectively). 8, 17 We showed 100% myeloid recovery, which proved the stability of our protocol for HID HSCT without ex vivo T-cell depletion in paediatric patients. In this study, the incidence of acute GVHD grade 3-4 (14.3%) was similar to that in a previous report in paediatric patients (13.8%) 11 and a report in adults (13.4%), 12 which confirms again the advantage of this HID transplantation protocol in inducing immune tolerance. Anti-thymoglobulin, other combined immunosuppressants and the use of a graft of G-CSF mobilised BM, combined with G-CSF mobilised peripheral blood, might contribute to maintaining T-cell hyporesponsiveness and polarisation from T helper 1 (Th1) to Th2, which would improve their capacity for immune tolerance. 18 In the current study, marked improvement in OS in treatment era 08-11 was recorded, compared with the previous era (02-07). A comparison in CR1/CR2 patients was performed to control for the influence of more high-risk patients in the previous era. A tendency toward superior LFS, inferior TRM and relapse in the recent era was recorded, although there was no statistical power or significance. This outcome suggests that inclusion of more high-risk patients in the previous era did have an impact on LFS. Statistical significance still exists for OS. This finding might be attributed partially to the improvement in supportive care, including the following aspects practiced routinely in the recent treatment era: (i) series of monitoring with Galactomanan assay for Aspergillus and PCR assay for CMV, EBV and adenovirus; (ii) pre-emptive treatments, including antifungal agents, ganciclovir and rituximab; (iii) high-resolution computed tomography scanning for any patients with fever or symptoms in the respiratory tract; (iv) pre-emptive intervention with modified DLI, according to positive findings during sequential monitoring of MRD; and (v) maturation of the collaboration in HSCT staff. To predict relapse, MRD has been monitored at our institution since 2006, at designated time points after HSCT. Patients with confirmed MRD after transplant are planned to receive preemptive modified DLI in the absence of uncontrolled GVHD for the prevention of relapse. 13 Therapeutic chemotherapy, followed by modified DLI, has been used in patients who relapsed after HSCT, with long-term of survival of B40%, which contributed to the improved overall survival. 19 It should be noted that scores on the Play-Performance Scale are appropriate for use with children aged 1-16 years. 20 To maintain a consistent evaluation system for quality of life, the performance statuses of paediatric patients aged 17 and 18 years were adapted to a similar scale in the current study.
Our protocol has not been applied in Caucasian populations. Recently, Bartolomeo et al.
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, from the Perugia group, reported the results of unmanipulated, G-CSF-primed BM transplantation from HID family donors in high-risk haematological malignancies. Andrea Velardi commented in the journal Blood that the protocol shared in common primary features with ours. 22 It included a chemotherapybased conditioning regimen, G-CSF-primed grafts and intensified immunosuppressive strategies. Hence, our unmanipulated HID approach might also be feasible in Caucasian populations.
This study revealed the outcomes of unmanipulated HID HSCT in paediatric patients with acute leukaemia, which are among the best reported. The benefits of this transplant setting suggest that related HID donors might be considered in patients lacking identical sibling donors, which would be especially beneficial for smaller-sized families. Additional prospective, multi-centre studies among experienced transplant centre are necessary to extend these results.
